GlassScriptPhysician profile
Gutteridge Jean-Charles
NPI 1598803470
$1,174.13
in general payments reported to CMS, 2019-2025
14 companies · $89.74 in 2025
The $89.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $237 · 2021: $71.89 · 2022: $52.73 · 2023: $397 · 2024: $159 · 2025: $89.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $280.28 | 2023-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $167.16 | 2020-2024 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $158.80 | 2019-2025 | |
| Exact Sciences Corporation | $81.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $77.78 | 2020-2024 | Farxiga, Airsupra |
| Amgen INC. | $76.10 | 2019-2024 | Krystexxa, Repatha |
| Redhill Biopharma INC. | $59.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $54.44 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.15 | 2024 | |
| Pfizer INC. | $44.67 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $41.59 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.36 | 2021 | |
| Lilly USA, LLC | $33.93 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $19.48 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gutteridge Jean-Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.